Comparison of two suspension injection tracers of nano activated carbon and methylene blue in mapping and tracing of sentinel lymph nodes of patients with endometrial cancer.

Objectives: To analyze the application efficiency of two tracers for sentinel lymph node mapping in patients with endometrial cancer. Methods: The records of endometrial cancer patients treated in our hospital from July 2019 to July 2021 were selected. Among them, 29 patients received methylene blue suspension injection and 33 patients received nano activated carbon suspension injection. The staining of sentinel lymph nodes was recorded and the application efficiency of two different tracers were analyzed. Results: Total detection rate, average number of sentinel lymph nodes and bilateral detection rate of nano activated carbon suspension injection were significantly higher than those of methylene blue suspension injection (P<0.05). Detection accuracy, positive predictive value and sensitivity of nano activated carbon suspension injection were significantly higher than those of methylene blue suspension injection (P<0.05). Incidence of complications was the same in the two groups (P>0.05). Tracing time of nano activated carbon suspension injection was significantly lower than that of methylene blue suspension injection, and the total duration was significantly higher than that of methylene blue suspension injection (P<0.05). Conclusion: Nano activated carbon can obtain good detection effect in sentinel lymph node recognition in endometrial cancer patients, with shorter tracing time and higher total duration than methylene blue suspension.

A proper triage for detecting women with high-risk human papillomavirus genotypes other than HPV16/18.

OBJECTIVE: To evaluate the effect of human papillomavirus (HPV) L1 capsid protein detection in cervical exfoliated cells as a proper triage for women with high-risk human papillomavirus (hrHPV) genotypes other than HPV 16/18. STUDY DESIGN: From January 2013 to June 2015, a total of 513 women aged 30-65 years infected with non-16/18 hrHPV were enrolled into the study. Primary HPV testing, HPV 16/18 genotyping and Papanicolaou (Pap) test were performed in all eligible women. HPV L1 capsid protein was detected by immunocytochemistry in cervical exfoliated cells. All hrHPV positive women underwent colposcopy and further biopsy if indicated. Relationships between HPV L1 capsid protein expression and histologic diagnosis, as well as cytology were analyzed. RESULTS: The positive expression rate of HPV L1 capsid protein in CIN2+ group was significantly lower than that in CIN1 or better group (16.3% vs. 66.7%, P=0.000). Compared with the Pap test, HPV L1 detection achieved higher sensitivity (83.7% vs. 51.2%, P=0.000), higher negative predictive value (NPV) (95.3% vs. 88.6%, P=0.002), and significant lower specificity (66.7% vs.76.1%, P=0.002) while identifying CIN2+. Compared with the Pap test, HPV L1 detection achieved higher sensitivity (89.7% vs. 51.7%, P=0.008), higher NPV (99.0% vs. 96.2%, P=0.043), and significant lower specificity (61.2% vs.73.8%, P=0.000) while identifying CIN3+. CONCLUSION: Because of its higher sensitivity and NPV than that of Pap test, HPV L1 capsid protein detection in cervical exfoliated cells reduces the missed identification of high-grade cervical intraepithelial neoplasia (CIN) in women with hrHPV genotypes other than HPV 16/18. HPV L1 capsid protein detection could be a potential triage for women with non-16/18 hrHPV infection.

Clinical evaluation of improved MyoSure hysteroscopic tissue removal system for the resection of type II submucosal myomas.

This study aims to determine whether clinical evaluation of improved MyoSure hysteroscopic tissue removal system can remove type II submucosal myomas with safety and high success rate of the first operation.Fifty-three patients with type II submucosal myomas hospitalized in the Huzhou Maternity and Child Care Hospital were enrolled in this study. The submucosal myomas were with the diameter of >2 cm and ≤5 cm. All patients have surgical indications.Fifty-one of 53 hysteromyomas were successfully resected through 1-time operation. The average time was 37.92 ±â€Š18.57 minutes, average amount of bleeding: 24.80 ±â€Š12.12 mL, average length of stay: 2.02 ±â€Š0.14 days. One patient had a transient postoperative fever and one patient had slight fluid overload with hyponatremia.The success rate of the first operation for resecting type II submucosal myomas showed an increase using improved MyoSure hysteroscopic tissue removal system, which can be a new, safer, and more efficient operation for treating type II submucosal myomas.